Alteration in cardiac PI3K/Akt/mTOR and ERK signaling pathways with the use of growth hormone and swimming, and the roles of miR21 and miR133

Palabiyik,Orkide; Tastekin,Ebru; Doganlar,Zeynep  Banu; Tayfur,Pinar; Dogan,Ayten; Vardar,Selma  Arzu

doi:10.3892/br.2018.1179

Alteration in cardiac PI3K/Akt/mTOR and ERK signaling pathways with the use of growth hormone and swimming, and the roles of miR21 and miR133

Authors:
- Orkide Palabiyik
- Ebru Tastekin
- Zeynep Banu Doganlar
- Pinar Tayfur
- Ayten Dogan
- Selma Arzu Vardar
View Affiliations

Affiliations: Department of Medical Services and Techniques, Trakya University Health Services Vocational College, Edirne 22030, Turkey, Department of Pathology, Trakya University Faculty of Medicine, Edirne 22030, Turkey, Department of Medical Biology, Trakya University Faculty of Medicine, Edirne 22030, Turkey, Department of Physiology, Trakya University Faculty of Medicine, Edirne 22030, Turkey
Published online on: December 13, 2018 https://doi.org/10.3892/br.2018.1179
Pages: 97-106
Copyright: © Palabiyik et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Athletes misuse recombinant human growth hormone (r‑hGH) to enhance their performance. Although r‑hGH is known to increase cardiac hypertrophy, the underlying molecular mechanism remains unclear. The aim of the present study was to investigate the role of r‑hGH in cardiac intracellular signaling pathways and of miR‑21 and miR‑133 expression in rat hearts during exercise. A total of 36 adult male Sprague‑Dawley rats were divided into sedentary control (SC, n=9), swimming exercise (SE, n=8), r‑hGH (GH, n=10) and swimming exercise plus r‑hGH (SE‑GH, n=9) groups. The exercise groups completed a 1‑h swimming exercise 5 times a week for 8 weeks. Subcutaneous r‑hGH was administered as 0.3 mg/kg/day. Phosphoinositide‑3‑kinase (PI3K), serine/threonine protein kinase 1 (AKT1), extracellular signal‑regulated kinase (ERK), microRNA (miR)‑21 and miR‑133 expression was evaluated in ventricular muscle by real‑time quantitative polymerase chain reaction. Protein expression of PI3K, AKT1, ERK and mechanistic target of rapamycin (mTOR) was also assessed by immunohistochemistry. Statistical differences were analyzed by two‑way ANOVA. PI3K and AKT1 expression and the gene and protein levels was notably increased in the SE‑GH group compared with in SC ventricular tissues (P<0.05). mTOR protein expression was higher in the GH, SE and SE‑GH groups compared with in the SC group (P<0.05, <0.05 and <0.001, respectively). ERK gene/protein expression was similar across all groups. miR‑21 and miR‑133 levels in ventricular muscle were higher in the SE and GH groups than those in the SC group. In summary, growth hormone application coupled with swimming exercise appeared to affect the PI3K/AKT/mTOR signaling pathway in the left ventricular tissue of rats; however, ERK signaling pathway appeared inactive in physiological left ventricular hypertrophy caused by swimming and GH administration over 8 weeks. Furthermore, GH treatment resulted in increased miR‑21 and miR‑133 expression. Future study by our group will aim to assess the effects of higher dose GH treatment.

View Figures

View References

1	Graham MR, Baker JS, Evans P, Kicman A, Cowan D, Hullin D, Thomas N and Davies B: Physical effects of short-term recombinant human growth hormone administration in abstinent steroid dependency. Horm Res. 69:343–354. 2008.PubMed/NCBI View Article : Google Scholar
2	Jenkins PJ: Growth hormone and exercise. Clin Endocrinol (Oxf). 50:683–689. 1999.PubMed/NCBI View Article : Google Scholar
3	Castellano G, Affuso F, Conza PD and Fazio S: The GH/IGF-1 Axis and Heart Failure. Curr Cardiol Rev. 5:203–215. 2009.PubMed/NCBI View Article : Google Scholar
4	Colao A, Marzullo P, Di Somma C and Lombardi G: Growth hormone and the heart. Clin Endocrinol (Oxf). 54:137–154. 2001.PubMed/NCBI View Article : Google Scholar
5	World Anti-Doping Agency: The 2010 Prohibited List. International Standard. https://www.wada-ama.org/sites/default/files/resources/files/WADA_Prohibited_List_2010_EN.pdf. Accessed September 19. 2009.
6	Voss SC, Giraud S, Alsayrafi M, Bourdon PC, Schumacher YO, Saugy M and Robinson N: The effect of a period of intensive exercise on the isoform test to detect growth hormone doping in sports. Growth Horm IGF Res. 23:105–108. 2013.PubMed/NCBI View Article : Google Scholar
7	Ma Z, Qi J, Meng S, Wen B and Zhang J: Swimming exercise training-induced left ventricular hypertrophy involves microRNAs and synergistic regulation of the PI3K/AKT/mTOR signaling pathway. Eur J Appl Physiol. 113:2473–2486. 2013.PubMed/NCBI View Article : Google Scholar
8	Heineke J and Molkentin JD: Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol. 7:589–600. 2006.PubMed/NCBI View Article : Google Scholar
9	Guertin DA and Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell. 12:9–22. 2007.PubMed/NCBI View Article : Google Scholar
10	Sugden PH and Clerk A: ‘Stress-responsive’ mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res. 83:345–352. 1998.PubMed/NCBI
11	Purcell NH, Wilkins BJ, York A, Saba-El-Leil MK, Meloche S, Robbins J and Molkentin JD: Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc Natl Acad Sci USA. 104:14074–14079. 2007.PubMed/NCBI View Article : Google Scholar
12	Hutvágner G and Zamore PD: A microRNA in a multiple-turnover RNAi enzyme complex. Science. 297:2056–2060. 2002.PubMed/NCBI View Article : Google Scholar
13	Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004.PubMed/NCBI View Article : Google Scholar
14	Bao H, Hu S, Zhang C, Shi S, Qin W, Zeng C, Zen K and Liu Z: Inhibition of miRNA-21 prevents fibrogenic activation in podocytes and tubular cells in IgA nephropathy. Biochem Biophys Res Commun. 444:455–460. 2014.PubMed/NCBI View Article : Google Scholar
15	Da Costa Martins PA and De Windt LJ: Targeting microRNA targets. Circ Res. 111:506–508. 2012.PubMed/NCBI View Article : Google Scholar
16	Cheng YS, Tang YQ, Dai DZ and Dai Y: AQP4 knockout mice manifest abnormal expressions of calcium handling proteins possibly due to exacerbating pro-inflammatory factors in the heart. Biochem Pharmacol. 83:97–105. 2012.PubMed/NCBI View Article : Google Scholar
17	Da Costa Martins PA and De Windt LJ: MicroRNAs in control of cardiac hypertrophy. Cardiovasc Res. 93:563–572. 2012.PubMed/NCBI View Article : Google Scholar
18	Wang L, Li X, Zhou Y, Shi H, Xu C, He H, Wang S, Xiong X, Zhang Y, Du Z and et al: Downregulation of miR-133 via MAPK/ERK signaling pathway involved in nicotine-induced cardiomyocyte apoptosis. Naunyn Schmiedebergs Arch Pharmacol. 387:197–206. 2014.PubMed/NCBI View Article : Google Scholar
19	Dong DL, Chen C, Huo R, Wang N, Li Z, Tu YJ, Hu JT, Chu X, Huang W and Yang BF: Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy: A novel mechanism for progressive cardiac hypertrophy. Hypertension. 55:946–952. 2010.PubMed/NCBI View Article : Google Scholar
20	Dong S, Ma W, Hao B, Hu F, Yan L, Yan X, Wang Y, Chen Z and Wang Z: microRNA-21 promotes cardiac fibrosis and development of heart failure with preserved left ventricular ejection fraction by up-regulating Bcl-2. Int J Clin Exp Pathol. 7:565–574. 2014.PubMed/NCBI
21	DA Silva ND Jr, Fernandes T, Soci UP, Monteiro AW and Phillips MI and DE Oliveira EM: Swimming training in rats increases cardiac MicroRNA-126 expression and angiogenesis. Med Sci Sports Exerc. 44:1453–1462. 2012.PubMed/NCBI View Article : Google Scholar
22	Oliveira EM, Sasaki MS, Cerêncio M, Baraúna VG and Krieger JE: Local renin-angiotensin system regulates left ventricular hypertrophy induced by swimming training independent of circulating renin: A pharmacological study. J Renin Angiotensin Aldosterone Syst. 10:15–23. 2009.PubMed/NCBI View Article : Google Scholar
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
24	Hirata Y, Murai N, Yanaihara N, Saito M, Saito M, Urashima M, Murakami Y, Matsufuji S and Okamoto A: MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma. BMC Cancer. 14(799)2014.PubMed/NCBI View Article : Google Scholar
25	Iijima Y, Seike M, Noro R, Ibi T, Takeuchi S, Mikami I, Koizumi K, Usuda J and Gemma A: Prognostic significance of PIK3CA and SOX2 in Asian patients with lung squamous cell carcinoma. Int J Oncol. 46:505–512. 2015.PubMed/NCBI View Article : Google Scholar
26	Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, Yang W, Smith TL, Shi D and Yu D: Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res. 10:6779–6788. 2004.PubMed/NCBI View Article : Google Scholar
27	Domenighetti AA, Danes VR, Curl CL, Favaloro JM, Proietto J and Delbridge LM: Targeted GLUT-4 deficiency in the heart induces cardiomyocyte hypertrophy and impaired contractility linked with Ca(2+) and proton flux dysregulation. J Mol Cell Cardiol. 48:663–672. 2010.PubMed/NCBI View Article : Google Scholar
28	Chung E and Diffee GM: Effect of aging on power output properties in rat skinned cardiac myocytes. J Gerontol A Biol Sci Med Sci. 66:1267–1273. 2011.PubMed/NCBI View Article : Google Scholar
29	Vikstrom KL, Bohlmeyer T, Factor SM and Leinwand LA: Hypertrophy, pathology, and molecular markers of cardiac pathogenesis. Circ Res. 82:773–778. 1998.PubMed/NCBI
30	Saugy M, Robinson N, Saudan C, Baume N, Avois L and Mangin P: Human growth hormone doping in sport. Br J Sports Med. 40((Suppl 1)): i35–i39. 2006.PubMed/NCBI View Article : Google Scholar
31	Cheng Y, Ji R, Yue J, Yang J, Liu X, Chen H, Dean DB and Zhang C: MicroRNAs are aberrantly expressed in hypertrophic heart: Do they play a role in cardiac hypertrophy? Am J Pathol. 170:1831–1840. 2007.PubMed/NCBI View Article : Google Scholar
32	Soci UP, Fernandes T, Hashimoto NY, Mota GF, Amadeu MA, Rosa KT, Irigoyen MC, Phillips MI and Oliveira EM: MicroRNAs 29 are involved in the improvement of ventricular compliance promoted by aerobic exercise training in rats. Physiol Genomics. 43:665–673. 2011.PubMed/NCBI View Article : Google Scholar
33	McMullen JR and Jennings GL: Differences between pathological and physiological cardiac hypertrophy: Novel therapeutic strategies to treat heart failure. Clin Exp Pharmacol Physiol. 34:255–262. 2007.PubMed/NCBI View Article : Google Scholar
34	McMullen JR, Shioi T, Zhang L, Tarnavski O, Sherwood MC, Kang PM and Izumo S: Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci USA. 100:12355–12360. 2003.PubMed/NCBI View Article : Google Scholar
35	Maehama T and Dixon JE: PTEN: A tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol. 9:125–128. 1999.PubMed/NCBI View Article : Google Scholar
36	Crackower MA, Oudit GY, Kozieradzki I, Sarao R, Sun H, Sasaki T, Hirsch E, Suzuki A, Shioi T, Irie-Sasaki J and et al: Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell. 110:737–749. 2002.PubMed/NCBI View Article : Google Scholar
37	Bai L, Liang R, Yang Y, Hou X, Wang Z, Zhu S, Wang C, Tang Z and Li K: MicroRNA-21 Regulates PI3K/Akt/mTOR Signaling by Targeting TGFβI during Skeletal Muscle Development in Pigs. PLoS One. 10(e0119396)2015.PubMed/NCBI View Article : Google Scholar
38	DeBosch B, Treskov I, Lupu TS, Weinheimer C, Kovacs A, Courtois M and Muslin AJ: Akt1 is required for physiological cardiac growth. Circulation. 113:2097–2104. 2006.PubMed/NCBI View Article : Google Scholar
39	Cho H, Thorvaldsen JL, Chu Q, Feng F and Birnbaum MJ: Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem. 276:38349–38352. 2001.PubMed/NCBI View Article : Google Scholar
40	Shioi T, McMullen JR, Tarnavski O, Converso K, Sherwood MC, Manning WJ and Izumo S: Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation. 107:1664–1670. 2003.PubMed/NCBI View Article : Google Scholar
41	Leontieva OV, Paszkiewicz GM and Blagosklonny MV: Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging. Aging (Albany NY). 4:899–916. 2012.PubMed/NCBI View Article : Google Scholar
42	Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, Conlon FL and Wang DZ: The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet. 38:228–233. 2006.PubMed/NCBI View Article : Google Scholar
43	Horie T, Ono K, Nishi H, Iwanaga Y, Nagao K, Kinoshita M, Kuwabara Y, Takanabe R, Hasegawa K, Kita T and et al: MicroRNA-133 regulates the expression of GLUT4 by targeting KLF15 and is involved in metabolic control in cardiac myocytes. Biochem Biophys Res Commun. 389:315–320. 2009.PubMed/NCBI View Article : Google Scholar
44	van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, Richardson JA and Olson EN: A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA. 103:18255–18260. 2006.PubMed/NCBI View Article : Google Scholar
45	Abdellatif M: The role of microRNA-133 in cardiac hypertrophy uncovered. Circ Res. 106:16–18. 2010.PubMed/NCBI View Article : Google Scholar